SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending due to its recent inclusion in the S&P MidCap 400 index, sparking anticipation of significant institutional buying. The community is actively discussing the company's strong financial position and its strategic pivot into Agentic AI orchestration, with many viewing it as an undervalued leader in the expanding automation sector despite ongoing debates about recent insider selling.

flyExclusive, Inc. engages in owning and operating jet aircraft for private jet passengers. It manages all aspects of the customer experience, in-house maintenance, repair, and overhaul services, including paint, interiors, and avionics capabilities. The company was founded by Thomas James Segrave, Jr. in 2015 and is headquartered in Kinston, NC.

flyExclusive Inc. - Ordinary Shares - Class A

flyExclusive (FLYX) is captivating market attention after being named an authorized Starlink Aviation dealer, signaling its entry into providing high-speed in-flight connectivity for private jets. This development has sparked extensive community discussion about potential short squeezes, massive trading volume, and the strategic expansion into MRO services. Traders are now evaluating whether this aerospace collaboration can sustain its impressive momentum amidst widespread bullish sentiment and ongoing volatility.

Aclarion, Inc. is a healthcare technology company, which engages in the provision of Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. It utilizes Artificial Intelligence to assist in quality control processes that flag spectroscopy data indicative of a poor MRS study. It offers NOCISCAN Suite, a revolutionary software suite that works with existing high field Magnetic Resonance systems and Magnetic Resonance Spectroscopy pulse sequence packages using an optimized protocol to conduct MRS exams of lumbar discs. The company was founded by James C. Peacock, David S. Bradford, and Jeffrey Lotz in 2008 and is headquartered in Broomfield, CO.

Aclarion Inc

Aclarion Inc. (ACON) is gaining significant traction following its corporate outlook, highlighting triple-digit growth for its AI back pain platform, a debt-free balance sheet with substantial cash, and expanding commercial reach. The community is actively debating the stock's exceptionally low share float and high cash-per-share value, anticipating a potential short squeeze and sustained upward momentum. However, some market participants express caution regarding historical volatility and perceived manipulation as volume surges around key price points.

SMX (Security Matters) Plc is a holding company, which engages in the provision of authentication solutions. It offers brand protection, authentication, and track and trace technology. The company was founded by Haggai Alon on July 1, 2022 and is headquartered in Dublin, Ireland.

SMX (Security Matters) Plc

SMX (Security Matters) PLC

SMX is trending amid a recent announcement regarding the conversion of convertible debt to equity, prompting intense and divided community discussion. Many traders are actively anticipating a massive short squeeze, citing high cost-to-borrow and limited share availability, with expectations of significant price appreciation. Conversely, others express caution, highlighting potential dilution and the stock's inherent volatility as key concerns, reflecting a speculative market battle.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending after receiving positive FDA feedback, confirming its sonelokimab therapy can proceed with a Biologics License Application for hidradenitis suppurativa without additional clinical trials. The community is actively discussing the potential for significant analyst price target upgrades and renewed buyout speculation, with many anticipating a substantial increase from current levels. Despite volatile trading, investors see this de-risked regulatory pathway as a strong catalyst for future appreciation, especially with an Investor Day announced for February.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Merck is generating significant buzz due to its aggressive pipeline expansion, highlighted by ongoing acquisition talks for promising biotechs like Revolution Medicines and its recent purchase of Cidara Therapeutics for an innovative flu treatment. The community sees these strategic moves, alongside positive data for new drugs like its oral cholesterol inhibitor and bladder cancer combo therapy, as Merck proactively addressing its impending Keytruda patent cliff. Investors are closely watching how these efforts position the pharmaceutical giant for sustained future growth.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

General Motors is trending as it initiates a substantial EV-related writedown and a strategic pivot from aggressive electric vehicle expansion amid cooling market demand. This move is being interpreted by the community as a pragmatic "EV demand reset," with discussions highlighting the company's renewed capital discipline and recent analyst upgrades that are tempering concerns over job cuts and controversial software changes.

Serve Robotics, Inc. engages in providing self-driving delivery. It designs, develops, and operates zero-emissions robots that serve people in public spaces, starting with food delivery. The company was founded by Ali Kashani, Dmitry Demeshchuk and MJ Burk Chun in 2017 and is headquartered in Redwood City, CA.

Serve Robotics Inc

Serve Robotics is trending amid reports of potential government support for the robotics industry, including discussions around an executive order, alongside recent endorsements from prominent industry leaders. The community is actively discussing the company's accelerating deployment of autonomous delivery robots, strategic partnerships for last-mile logistics, and its position in the "physical AI" sector, fueling optimism for its long-term growth trajectory.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending after experiencing a multi-day pullback, with investors keenly debating whether the stock is ripe for a bounce due to oversold technicals. While many anticipate a rebound, others express caution, highlighting a perceived lack of immediate AI catalysts compared to peers and Apple's recent market capitalization shift behind Alphabet. This dynamic has created a split in community sentiment, ranging from aggressive dip-buying to continued bearishness.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is trending due to recently updated revenue guidance for DefenCath extending into 2026 and 2027, which has unfortunately overshadowed the release of strong real-world evidence data for the product and its ongoing diversification through the Melinta acquisition. The community is sharply divided, with many expressing deep disappointment and accusations of mismanagement, while others view the resulting market reaction as an overdone sell-off and a significant buying opportunity for the company's long-term potential.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$BE Back to $140+. JMHO 
Also - Article available in Stocktwits News - &quot;Bloom Energy vs. Plug Power: Which One Will Dominate the Next Decade?&quot;

William Cosby

bruce carlson

$BE Looking 👀 at maybe $150+ in the near future

StockTwits for iOS

Gary Braker

StockTwits Web

Bloom Energy Corp

 Back to $140+. JMHO 
Also - Article available in Stocktwits News - "Bloom Energy vs. Plug Power: Which One Will Dominate the Next Decade?"

@StockBraker we know which own will dominate while the other one survives.

 we know which own will dominate while the other one survives.

Jeff Huffman

@sofiastocks Article seems to think Bloom has the advantage. What are your thoughts?

 Article seems to think Bloom has the advantage. What are your thoughts?

@StockBraker oh my. Bloom for certain. I’m in both. Plug has been ran so poorly. Mistakes. Losses and more losses. I hope plug survives. Averaged down from high single digits. Likely RS coming ig they don’t get a quorum on the 29 January. If the 1.5B share are approved you can bet the farm they will use them. 350m shares in 2023. Possibly 3B in 2026. 
Bloom keeps doing all the right things. Should be 3-500 in 3-4 years. Maybe higher. Will see

 oh my. Bloom for certain. I’m in both. Plug has been ran so poorly. Mistakes. Losses and more losses. I hope plug survives. Averaged down from high single digits. Likely RS coming ig they don’t get a quorum on the 29 January. If the 1.5B share are approved you can bet the farm they will use them. 350m shares in 2023. Possibly 3B in 2026. 
Bloom keeps doing all the right things. Should be 3-500 in 3-4 years. Maybe higher. Will see